The high failure rate of drugs late in clinical development is an indication that nonclinical in vitro models and animal models are not accurately predicting compound performance in humans. Only 1 out of 10,000 molecules identified by pharmaceutical companies as a potential drug candidate is successfully advanced through FDA approval. Drug toxicity in general and drug-induced liver injury (DILI) in particular, represent the major cause of drug attrition or removal from the marketplace. There is a critical gap between the need for predictive in vitro platforms to evaluate the effects of compounds on human health and the availability of solutions which meet the throughput and accuracy required. To meet this need for increased biological relevance, the next generation of toxicity testing is beginning to incorporate fluidics and more complex cellular models into in vitro compound safety and efficacy testing. Non-fluidic (static) tissue culture plates have been a staple of the in vitro pharmaceutical testing market for decades and are the major model system used for liver safety testing. However, static cell culture systems fail to generate biologically relevant gradient drug exposures and may lack the viability and metabolic competency essential for safety testing. Additionally, these static systems do not allow for discrimination between primary drug effects and those mediated by metabolic breakdown products or cellular responses. While these static systems afford a picture of the acute toxicity of the compound itself, this picture is incomplete, at best, and potentially leads to the progression of compounds with serious safety issues into animal studies and clinical trials. These late stage failures come at huge financial costs to pharmaceutical companies, creating a significant need in the marketplace We have developed the SciFlowTM 1000 Fluidic Culture System to address existing shortcomings in drug safety testing. SciFlow 1000 is an innovative, gravity driven, fluidic tissue culture system providing highly biologically relevant compound exposures, and an innate ability to distinguish between parent drug and metabolite effects. The SciFlow System is based on a standard, SBS compliant, 96-well plate format with the addition of fluidic pathways connecting the wells along each row of the plate. This enables the evaluation of gradient compound concentrations on cells, under dynamic one way fluidic conditions that are more representative of the in vivo environment. SciFlow is designed as an open platform, supporting the culture of many cell types, in both two-dimensional (2D) and three-dimensional (3D) formats, and in a more biologically relevant fashion. To validate its diverse culture capabilities, SciFlow?s compartments have been populated with cells representing a wide variety of phenotypes including primary liver cells (hepatocytes: human, dog, rat, mouse, etc.) and many diverse cell lines (HepG2, HepaRG, Caco2, etc.). Preliminary compound toxicity studies have been completed, utilizing many biochemical and high content imaging assays to assess cellular outcomes. This proposal describes the development of an SOP to leverage the benefits of the SciFlow 1000 to provide improved drug-induced liver injury (DILI) prediction.
The aims of this project are to: 1) Optimize existing exposure and assay protocols in the SciFlow 1000. 2) Use a library of 21 compounds (i.e. training data-set) of known and varying DILI on 3 liver cell models (primary human hepatocytes, co-cultures of primary human hepatocytes and non-parenchymal cells, and HepaRG cells) to drive selection of a panel assays to include in a final SciFlow DILI predictive SOP. 3) Demonstrate the capabilities of the SciFlow DILI predictive SOP in two blinded studies. This work will be completed in collaboration with the UNC Eshelman School of Pharmacy Institute for Drug Safety Sciences. The outcomes of this study will be a complete solution for conducting predictive toxicology analyses on new drug candidates with previously unattainable levels of sensitivity and specificity. These accurate in vitro to in vivo extrapolations (IVIVE) will decrease the number of compounds with serious toxicity liabilities proceeding into the later pre-clinical and early clinical drug development, saving pharmaceutical companies both time and money while enabling the ultimate goal of more rapidly providing safe and effective therapeutics.
Standardization of a Fluidic In vitro Exposure System for IVIVE Predictive Toxicity Data The high failure rate of drugs in late stage clinical development is an indication that nonclinical in vitro and pre- clinical animal models consistently fail to accurately predict compound efficacy and toxicity in the human body. This is because currently available static tissue culture systems and animal testing often fail to adequately reproduce human physiology and to identify dangerous compounds, resulting in expensive late stage compound failures. We have developed the SciFlow 1000, a 96 well microfluidic tissue culture system that incorporates fluid movement with compound and metabolite exposure gradients into a benchtop model that when combined with liver cells, produces a superior model of human physiology and mimics compound exposure in the human liver. This Phase II application outlines the optimization of compound dosing and assays, with the goal of developing a well-validated method for predicting drug-induced liver injury that leverages the unique benefits of the SciFlow 1000.
